Peer-reviewed veterinary case report
Toceranib phosphate side effects in cats with tumors
By Merrick, C H et al.·Published in Veterinary and comparative oncology·2017·VCA Bay Area Veterinary Specialists & Emergency Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
- Species:
- cat
Plain-English summary
Fifty-five cats with cancer were treated with a medication called toceranib phosphate (Palladia) to see how well they tolerated it. While some cats experienced side effects like low blood cell counts and gastrointestinal issues, these were less common than in dogs treated with the same drug. Overall, the study found that most cats handled the treatment well, with only a few showing significant toxicity. More research is needed to refine dosing and assess how effective toceranib is for treating cancer in cats.
People also search for: cat cancer treatment side effects · toceranib phosphate for cats · Palladia toxicity in cats
Abstract
The purpose of this study was to describe the toxicity profile of toceranib phosphate in tumour bearing cats. Medical records were reviewed from seven institutions. Patients with incomplete medical records and those receiving concurrent chemotherapy or NSAIDs (non-steroidal anti-inflammatory) were excluded. Fifty-five cats met the inclusion criteria. Carcinoma was diagnosed in 55% of cases. Median oral toceranib dose was 2.7 mg kgand was most commonly administered on Monday, Wednesday and Friday. Thrombocytopenia (16.3%) and neutropenia (9.1%) were the most common haematologic toxicities. Azotemia (14.5%) and alanine aminotransferase (ALT) elevations (7.2%) were the most frequently encountered biochemical alterations. Gastrointestinal (GI) toxicity was seen in 21.8% of cats, and was lower than previously reported in dogs. The results of this study showed that treatment of cats with toceranib is well-tolerated and toxicity is uncommon. Additional studies to define a more structured dosing schedule and to evaluate the efficacy of toceranib in the treatment of feline cancers are needed.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27041701/